Robert Cornell, MD
Urology · Houston, TXNPI 1457331803
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.9% of the total across 240 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by Boston Scientific at 30.2% of the total. Reporting peaked in 2021 at $1,602 and has fallen 66.5% since, to $536 in 2025.
Across 240 payments — averaging $32.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$2K
- Coloplast$2K
- Astellas Pharma US Inc$942
- Pfizer$846
- Axonics, Inc.$668
- Endo Pharmaceuticals Inc.$232
- plus $804 from 15 others
Across 65 payments — averaging $10,568 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$617K
- Gilead$70K
What the payments were for
- Consulting fees$4005%
- Food & beverage$7,25693%
- Education$1232%
- Other$330%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 66 | $2,356 |
| Coloplast | 35 | $1,965 |
| Astellas Pharma US Inc | 43 | $942 |
| Pfizer | 37 | $846 |
| Axonics, Inc. | 11 | $668 |
| Endo Pharmaceuticals Inc. | 13 | $232 |
| Medtronic(2 entities) | 3 | $168 |
| Antares Pharma, Inc. | 10 | $168 |
| Convatec Inc. | 4 | $88 |
| Ferring Pharmaceuticals Inc. | 3 | $64 |
| Olympus America Inc. | 2 | $57 |
| Acerus Pharmaceuticals Corporation | 3 | $51 |
| Halozyme Inc | 2 | $36 |
| Wound Management Technologies, Inc | 1 | $36 |
| Innovation Technologies Inc | 1 | $33 |
| Travere Therapeutics, Inc. | 1 | $20 |
| AbbVie | 1 | $20 |
| 180 Medical, Inc. | 1 | $19 |
| Reflow Medical Inc | 1 | $16 |
| Duchesnay USA Incorporated | 1 | $16 |
| Mission Pharmacal Company | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TITAN$820
- Axonics r-SNM System$458
- Coloplast TFL Drive$166
- GENERAL ERECTILE DYSFUNCTION$132
- INTERSTIM$118
- AMS$105
- AMS 700$102
- GENERAL BPH$101
How this compares
$7,812 in reported general payments places this provider in the 70th percentile of 878 urology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 12 | $168,539 |
| MyrbetriqMirabegron | 104 | $83,764 |
| Mirabegron ErMirabegron | 16 | $9,210 |
| Tadalafil | 76 | $7,462 |
| Tamsulosin Hcl | 631 | $7,410 |
| Finasteride | 407 | $4,481 |
| Testosterone Cypionate | 72 | $4,121 |
| Testosterone | 14 | $2,121 |
| CefuroximeCefuroxime Axetil | 140 | $2,055 |
| Cabergoline | 43 | $1,963 |
| Anastrozole | 499 | $1,940 |
| Potassium Citrate ErPotassium Citrate | 22 | $1,820 |
| Estradiol | 16 | $1,786 |
| Risedronate Sodium | 14 | $1,516 |
| Cefixime | 49 | $1,498 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $942 | $252,303116 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 878 urology providers in Texas.
Other urology in Houston
- Arun RaiHouston$920K
- Donald GriffithHouston$732K
- Jonathan Clavell HernandezHouston$500K
- Ashish KamatHouston$481K
- Mohit KheraHouston$428K
- Ricardo GonzalezHouston$314K
- Richard LinkHouston$261K
- Steven CanfieldHouston$256K
- Run WangHouston$195K
- Kathleen KobashiHouston$159K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.